Physician profile
Stephen J Lenhoff
NPI 1477517456
$1,285.17
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $170 · 2021: $615.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $298.87 | 2019-2021 | |
| Esperion Therapeutics, INC. | $218.05 | 2020-2021 | |
| Akcea Therapeutics, INC. | $171.61 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $124.63 | 2019-2021 | |
| Bardy Diagnostics, INC. | $70.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $68.05 | 2020-2021 | |
| Ge Healthcare | $61.28 | 2019 | |
| Amarin Pharma, INC. | $60.75 | 2020-2021 | |
| Medtronic, INC. | $33.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.35 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.39 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $28.73 | 2021 | |
| Novo Nordisk INC | $24.02 | 2021 | |
| Edwards Lifesciences Corporation | $22.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.78 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.32 | 2021 | |
| Abbott Laboratories | $11.82 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lenhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.